Compare Davita Inc (DVA) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Davita Inc trades at $179.02 (market cap $11.38B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.14. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | VOOG | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $85.42 |
52-Week Low | $103.87 | $65.32 |
Enterprise Value | $24.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $85.42, up 0.68% on the day and near a 52-week high. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI suggests overbought conditions. Recent news highlights institutional accumulation, such as Apella Capital increasing its stake by 463.2% in Q2 2026, and positive coverage from financial outlets comparing its low expense ratio and growth focus favorably against peers.
The outlook for VOOG remains positive, driven by exposure to large-cap growth stocks and strong institutional interest. Key risks include high concentration in technology sectors, making it vulnerable to sector-specific downturns, and broader market volatility. Its low expense ratio of 0.07% and historical outperformance present a compelling case for growth-oriented investors, but caution is warranted given elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
